Pharmaceutical Technology

JULY 25, 2022

AstraZeneca and Daiichi Sankyo have received Priority Review for their supplemental Biologics License Application (sBLA) from the US Food and Drug Administration (FDA) of antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), to treat unresectable or metastatic HER2-low breast cancer in adults.

HR 130

HR Hormones Licensing Licensing 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

DECEMBER 12, 2022

Along with data from its antibody-drug conjugates and oral selective oestrogen receptor degrader (SERD) camizestrant reported earlier, AZ presented results of the CAPItello trial of AKT inhibitor capivasertib in combination with injectable SERD Faslodex (fulvestrant) in hormone receptor positive, HER2-negative advanced breast cancer.

HR 104

HR Hormones Trials Drugs 104

Roots Analysis

OCTOBER 24, 2023

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. Antibody-Drug Conjugates: ADCs are monoclonal antibodies (mAbs) attached to surface antigens by chemical or a liable linker.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 69

Drugs Gene Editing Antibody Medicine 69

pharmaphorum

NOVEMBER 6, 2020

Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been on the market for several years and has proven to be effective across a wide range of oncology indications. billion in cash. The transaction is expected to close at the end of 2020.

Antibody 84

Antibody Hormones Trials Clinical Trials 84

Roots Analysis

MARCH 21, 2022

Subcutaneous biologics – current market landscape. There has been a significant increase in the number of biologics, specifically the new generation molecules, such as monoclonal antibodies, in the late-stage clinical studies ( phase II / phase III ). Of these, 50 players have approved subcutaneous biologics. Our Social Media Platform.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Marketing 52

pharmaphorum

JULY 14, 2022

The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use.

Drugs 103

Drugs Hormones Genome Genomics 103

pharmaphorum

SEPTEMBER 14, 2020

US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin). Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics. billion equity investment in 5.0

Genetics 52

Genetics Development Drugs Protein 52

pharmaphorum

JANUARY 10, 2023

The drug offers an oral alternative to injectable therapies for anaemia associated with chronic kidney disease; 4) Deucravacitinib : Bristol-Myers Squibb looks set for a winner with this first-in-class oral TYK2 inhibitor, which according to Clarivate has the potential to fill a gap in the treatment armamentarium for moderate to severe psoriasis.

Drugs 52

Drugs Gene Therapy Insulin Antibody 52

pharmaphorum

AUGUST 16, 2022

The deal gives it worldwide ownership of Trodelvy (sacituzumab govitecan), a first-in-class TROP2 antibody-drug conjugate drug it acquired as part of its $21 billion takeover of Immunomedics in 2020.

Licensing 52

Licensing Licensing Hormones Drugs 52

pharmaphorum

JULY 13, 2022

Merck – known as MSD outside the US and Canada – is paying $290 million upfront for global co-development and co-marketing rights to ODM-208, a steroid synthesis inhibitor, as well as follow-up compounds in the same class. Further financial terms have not been disclosed.

Licensing 52

Licensing Licensing Hormones Sales 52

pharmaphorum

AUGUST 3, 2022

Cell therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) for lymphoma and leukaemia together brought in $368 million, up 68%, while antibody drug conjugate Trodelvy (sacituzumab govitecan) rose 79% to $159 million thanks to increased uptake in triple-negative breast cancer.

Sales 104

Sales Hormones Drugs Antibody 104

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Hormones Antibody 52

Delveinsight

AUGUST 2, 2020

The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

FEBRUARY 21, 2022

” The antibody-drug conjugate is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the DESTINY-Breast03 study looks set to expand its use into second-line treatment in breast cancer. AZ paid a hefty $1.4

Trials 131

Trials Sales Hormones Drugs 131

pharmaphorum

DECEMBER 23, 2020

2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”.

Marketing 94

Marketing Gene Silencing Gene Drugs 94

The Pharma Data

SEPTEMBER 28, 2021

The CHMP’s recommendation will now be reviewed by the ecu Commission for marketing authorization within the European Union. Triple-negative carcinoma may be a sort of carcinoma that tests negative for estrogen hormone receptors, progesterone hormone receptors and overexpression of human epidermal protein receptor 2 (HER2).

Hormones 52

Hormones Medicine Clinical Research Research 52

pharmaphorum

AUGUST 8, 2022

It has the potential to be a sizeable new indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate, and central to AZ and Daiichi Sankyo’s hopes of unlocking multibillion-dollar sales for the drug.

HR 52

HR Hormones Sales Antibody 52

XTalks

FEBRUARY 5, 2024

As we delve into the specifics of these best-selling oncology drugs, we uncover the underlying factors contributing to their market dominance, from clinical efficacy and safety profiles to strategic market positioning and patient accessibility. The worldwide net trade sales of Darzalex were $2.26 billion in the first quarter of 2023.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

AUGUST 15, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday that the US Food and Drug Administration (FDA) has granted marketing authorization for its combination treatment Akeega for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. The post ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition appeared first on Pharmaceutical Technology.

HR 162

HR Marketing Hormones FDA Approval 162

XTalks

MARCH 8, 2024

Despite the approvals, the market launches of Jubbonti and Wyost are uncertain due to ongoing patent litigation between Sandoz and Amgen. Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK.

Drugs 59

Drugs FDA Approval Production Immune Response 59

Delveinsight

AUGUST 6, 2020

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Among the 7MM geographies, the US accounted for the 54% share of the total hATTR market size. Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

XTalks

MARCH 22, 2021

The mega biotech acquisition deals, ranging between a quarter to over half a billion dollars, reflects the expanding oncology market, which was valued at $136.7 Despite setbacks due to the pandemic, the market is expected to recover and continue its march forward. The liquid biopsy market itself was valued at over $1.06

Life Science 110

Life Science Development Marketing Gene Expression 110

The Pharma Data

APRIL 23, 2021

Dostarlimab is a programmed death receptor-1 (PD-1)-blocking antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. The collaboration has resulted in three monospecific antibody drugs that have progressed into the clinic. L1 blocking antibodies. ligand 1 (PD?1/PD?L1)

Antibody 52

Antibody Hormones Licensing Licensing 52

XTalks

FEBRUARY 5, 2024

As we delve into the specifics of these best-selling oncology drugs, we uncover the underlying factors contributing to their market dominance, from clinical efficacy and safety profiles to strategic market positioning and patient accessibility. The worldwide net trade sales of Darzalex were $2.26 billion in the first quarter of 2023.

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them.

Pharma Companies 57

Pharma Companies Branding Development Marketing 57

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

pharmaphorum

MARCH 11, 2021

Diagnostics was never a Cinderella sector; Britain has the fifth largest in vitro diagnostics (IVD) market in Europe, not gigantic but significant nevertheless. The subsequent roll out of PCR testing has highlighted how effective and valuable relatively inexpensive tests can be in halting the spread of COVID-19.

In-Vitro 71

In-Vitro Containment Radiology Life Science 71

The Pharma Data

MARCH 25, 2021

The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

The Pharma Data

AUGUST 3, 2021

For the remainder of the year, we expect continued growth from Kyprolis use in combination with CD38 antibodies. Selling, General & Administrative (SG&A) expenses increased 7% driven by marketed product support due to increased customer engagement in response to the pandemic recovery and investment in new product launches.

Sales 52

Sales Production Antibody Development 52

Pfizer

JANUARY 27, 2023

This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives.

Research 112

Research Vaccination Vaccine Drugs 112

Drug Discovery World

FEBRUARY 21, 2023

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting. Trodelvy has been marketed for triple-negative breast cancer since 2021.

HR 52

HR Hormones Sales Antibody 52

Roots Analysis

MAY 21, 2024

Due to which, several big pharma companies and other industry stakeholders are actively contributing towards development of protein degradation therapies and technologies, contributing towards growth of targeted protein degradation market.

Protein 40

Protein Marketing Development Antibody 40

pharmaphorum

JUNE 6, 2022

In Trodelvy’s favour is that the outlook for patients with HR+/HER2- breast cancer who have progressed despite earlier hormonal therapies, CDK4/6 inhibitors and multiple lines of chemo is pretty bleak. months of extra life, as well as improvements in quality of life measures including fatigue.

HR 52

HR Hormones Trials Drugs 52